Low-incidence adverse events (AEs): An emerging challenge in chimeric antigen receptor T-cell (CAR-T) therapy

Cancer Pathogenesis and Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles